CTI BioPharma Corp.
CTI BioPharma Corp. Fundamental Analysis
CTI BioPharma Corp. (CTIC) shows moderate financial fundamentals with a PE ratio of -11.46, profit margin of -1.69%, and ROE of 13.18%. The company generates $0.1B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -75.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze CTIC's fundamental strength across five key dimensions:
Efficiency Score
WeakCTIC struggles to generate sufficient returns from assets.
Valuation Score
ExcellentCTIC trades at attractive valuation levels.
Growth Score
WeakCTIC faces weak or negative growth trends.
Financial Health Score
ExcellentCTIC maintains a strong and stable balance sheet.
Profitability Score
WeakCTIC struggles to sustain strong margins.
Key Financial Metrics
Is CTIC Expensive or Cheap?
P/E Ratio
CTIC trades at -11.46 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, CTIC's PEG of -0.11 indicates potential undervaluation.
Price to Book
The market values CTI BioPharma Corp. at -59.35 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -14.78 times EBITDA. This is generally considered low.
How Well Does CTIC Make Money?
Net Profit Margin
For every $100 in sales, CTI BioPharma Corp. keeps $-1.69 as profit after all expenses.
Operating Margin
Core operations generate -1.48 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $13.18 in profit for every $100 of shareholder equity.
ROA
CTI BioPharma Corp. generates $-72.30 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
CTI BioPharma Corp. generates limited operating cash flow of $-93.36M, signaling weaker underlying cash strength.
Free Cash Flow
CTI BioPharma Corp. generates weak or negative free cash flow of $-122.11M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.93 in free cash annually.
FCF Yield
CTIC converts -8.85% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-11.46
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.11
vs 25 benchmark
P/B Ratio
Price to book value ratio
-59.35
vs 25 benchmark
P/S Ratio
Price to sales ratio
22.23
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-2.84
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.23
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
13.18
vs 25 benchmark
ROA
Return on assets percentage
-0.72
vs 25 benchmark
ROCE
Return on capital employed
-1.78
vs 25 benchmark
How CTIC Stacks Against Its Sector Peers
| Metric | CTIC Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -11.46 | 28.25 | Better (Cheaper) |
| ROE | 1318.48% | 780.00% | Excellent |
| Net Margin | -168.76% | -20122.00% (disorted) | Weak |
| Debt/Equity | -2.84 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 1.23 | 4.66 | Neutral |
| ROA | -72.30% | -14687.00% (disorted) | Weak |
CTIC outperforms its industry in 3 out of 6 key metrics, particularly excelling in ROE, but lagging in Net Margin.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews CTI BioPharma Corp.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation